Targeting Memory T-Cells in Type 1 Diabetes, Indiana University Study
Published: Sep 23, 2013
Encouraging results from the T1DAL study (Targeting effector memory T cells with alefacept in new onset type 1 diabetes), led by Mark R. Rigby M.D., Ph.D. from Indiana University and Riley Hospital for Children in Indianapolis and sponsored by the Immune Tolerance Network (ITN) with additional support from JDRF, are published today in The Lancet Diabetes & Endocrinology.
Hey, check out all the research scientist jobs. Post your resume today!